Asceneuron
Developing disease modifying small molecule therapeutics with an initial focus on tauopathies and synucleinopathies (AD, PD)
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects its ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including one first in class for Parkinson’s disease, one best in class in Alzheimer’s disease and related disorders.
